Prime Medicine, Inc.
A biotechnology company developing "Prime Editing," a gene-editing technology that acts like a molecular word processor, able to search for and rewrite faulty DNA without cutting both strands like earlier CRISPR "scissors." Founded in 2019, Prime Medicine aims to turn this science into one-time treatments for serious inherited diseases, and its lead therapy targets chronic granulomatous disease, a rare immune disorder. The company takes its name from the Prime Editing technology it was built around.
Bought 84.0K
Bought 7.03M
Bought 7.03M
Bought 6.23M
Bought 800.0K · Sold 1.42M
Bought 400.0K
Bought 1.50M
Bought 125.0K
Bought 100.0K
Bought 20.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Liu David R.10% owner · 6 transactions | — | 20.24Mas of Jun 2025 | — | 84.0K | — |
| Nelsen RobertDirector, 10% owner · 7 transactions | — | 18.50Mas of Aug 2025 | — | 7.03M | — |
| Burow Kristina +7 co-filers10% owner · 6 transactions | — | 18.49Mas of Aug 2025 | — | 7.03M | — |
| ARCH Venture Fund XII, L.P. +2 co-filers10% owner · 2 transactions | — | 18.49Mas of Aug 2025 | — | 6.23M | — |
| Alphabet Inc. +6 co-filers10% owner · 58 transactions | — | 11.86Mas of Jun 2023 | — | 800.0K | 1.42M |
| Gottesdiener Keith MichaelSee Remarks, Director · 6 transactions | — | 8.44Mas of Oct 2024 | — | — | — |
| FMR LLCSee Remark 1 · 5 transactions | — | 8.03Mas of Oct 2022 | — | — | — |
| Cahill ThomasDirector · 2 transactions | — | 5.31Mas of Oct 2022 | — | 400.0K | — |
| Alphabet Inc. +3 co-filers10% owner · 1 transaction | — | 3.26Mas of Aug 2025 | — | 1.50M | — |
| Reine AllanChief Executive Officer, Director · 1 transaction | — | 125.0Kas of May 2025 | — | 125.0K | — |
| Lee Ann L.Chief Technical Officer · 1 transaction | — | 100.0Kas of May 2025 | — | 100.0K | — |
| Brudnick RichardChief Business Officer · 1 transaction | — | 20.0Kas of May 2025 | — | 20.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +21.90M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.